Ariad, MolecularMD Partner on Companion Dx for T315I Mutation | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Ariad Pharmaceuticals and MolecularMD today announced a collaboration under which MolecularMD will develop a companion diagnostic test to identify the T315I mutation of the BCR-ABL gene in patients with chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.